| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/31/2011 | WO2011017159A3 Broad spectrum erbb ligand binding molecules and methods for preparing and using them |
| 03/31/2011 | WO2011017132A3 Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
| 03/31/2011 | WO2011011847A8 Pharmaceutical composition for treating medical conditions and a method for treating alimentary disorders and related diseases |
| 03/31/2011 | WO2011009757A3 Use of human beta-defensin to influence the natural pigmentation process |
| 03/31/2011 | WO2011000962A3 Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means |
| 03/31/2011 | WO2010148079A9 Antimicrobial and antibiofilm activity of cathelicidins |
| 03/31/2011 | WO2010136897A3 Luxr mutants from vibrio fischeri auto induction expression systems using them |
| 03/31/2011 | WO2010134939A3 Mammalian genes involved in infection |
| 03/31/2011 | WO2010132725A3 Cyclin dependent kinase inhibitors and methods of use |
| 03/31/2011 | WO2010132580A3 Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
| 03/31/2011 | WO2010129890A3 Compounds and methods for inhibiting platelet aggregation |
| 03/31/2011 | WO2010120566A3 METHODS FOR TREATING IgE-MEDIATED DISORDER |
| 03/31/2011 | WO2010120509A3 Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities |
| 03/31/2011 | WO2010118169A3 Human protein scaffold with controlled serum pharmacokinetics |
| 03/31/2011 | WO2010108028A3 Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same |
| 03/31/2011 | WO2010093802A3 Therapeutic method for increasing pancreatic beta cell mass |
| 03/31/2011 | WO2010069331A3 Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders |
| 03/31/2011 | WO2010064132A8 Mutants of staphylokinase carrying amino and carboxy-terminal extensions for polyethylene glycol conjugation |
| 03/31/2011 | US20110078804 Angiogenin and Amyotrophic Lateral Sclerosis |
| 03/31/2011 | US20110077385 Protein arrays |
| 03/31/2011 | US20110077287 Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions |
| 03/31/2011 | US20110077217 Selectively depolymerized galactomannan polysaccharide |
| 03/31/2011 | US20110077211 Methods and compositions for treating luminal inflammatory disease |
| 03/31/2011 | US20110077210 Hdac regulation assays, compounds and therapeutic compositions |
| 03/31/2011 | US20110077209 Protein or glycoprotein from haliotis midae and its use as an immunotherapy agent |
| 03/31/2011 | US20110077208 Expression of secreted human alpha-fetoprotein in transgenic animals |
| 03/31/2011 | US20110077207 Method for treating inflammation |
| 03/31/2011 | US20110077206 Use of hnf4alpha for treatment of human malignant solid tumors through induction-differentiation therapy |
| 03/31/2011 | US20110077205 Production and Use of Antitumoral Cyclodepsipeptides |
| 03/31/2011 | US20110077204 Agent for Targeted Drug Delivery To Cerebral Neurons |
| 03/31/2011 | US20110077203 Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use |
| 03/31/2011 | US20110077202 Targeted Coagulation Factors and Method of Using the Same |
| 03/31/2011 | US20110077201 High affinity vegf-receptor antagonists |
| 03/31/2011 | US20110077200 Combination therapy using low-dose doxepin for the improvement of sleep |
| 03/31/2011 | US20110077199 Growth hormone polypeptides and methods of making and using same |
| 03/31/2011 | US20110077198 Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition |
| 03/31/2011 | US20110077197 Novel insulin derivatives having an extremely delayed time-action profile |
| 03/31/2011 | US20110077196 Non-standard insulin analogues |
| 03/31/2011 | US20110077195 Liquid preparation of physiologically active peptide |
| 03/31/2011 | US20110077194 Method for Treating or Preventing a Functional Vitamin B12 Deficiency in an Individual and to Medical Compositions for Use in Said Method |
| 03/31/2011 | US20110077193 Artemisinin Derivatives with Natural Amino Acids, Peptides, and Amino Sugars for the Treatment of Infection and Topical Condition in Mammals |
| 03/31/2011 | US20110077192 Novel Antibacterial Peptides |
| 03/31/2011 | US20110077191 Novel inhibitors of mammalian tight junction opening |
| 03/31/2011 | US20110077190 Selective Caspase Inhibitors and Uses Thereof |
| 03/31/2011 | US20110077189 Composition for stimulating natural killer cell activity |
| 03/31/2011 | US20110076347 Molecules Interfering with Binding of Calbindin to Inositol Monophosphatase for the Treatment of Mood Disorders |
| 03/31/2011 | US20110076342 Cancer peptide therapeutics |
| 03/31/2011 | US20110076326 Modified protein excipient for delayed-release tablet |
| 03/31/2011 | US20110076321 Self-adhesive polymer matrix containing sea algae extract |
| 03/31/2011 | US20110076317 Rapid establishment and/or termination of substantial steady-state drug delivery |
| 03/31/2011 | US20110076316 Scalable matrix for the in vivo cultivation of bone and cartilage |
| 03/31/2011 | US20110076298 Soluble stabilized trimeric hiv env proteins and uses thereof |
| 03/31/2011 | US20110076297 Peptides for Inducing Heterosubtypic Influenza T Cell Responses |
| 03/31/2011 | US20110076295 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| 03/31/2011 | US20110076288 Compositions for and Methods of Identifying Antigens |
| 03/31/2011 | US20110076286 Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
| 03/31/2011 | US20110076281 Bmp-1 procollagen c-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders |
| 03/31/2011 | US20110076276 Novel HIV reverse transcriptase inhibitors |
| 03/31/2011 | US20110076261 Antifungal Drug Delivery System |
| 03/31/2011 | US20110076259 Detection of risk of pre-eclampsia |
| 03/31/2011 | US20110076258 Methods of modulating t cell- dependent immune responses |
| 03/31/2011 | US20110076251 Novel therapeutic agents against hepatitis |
| 03/31/2011 | US20110076250 Biodegradable Absorbents and Methods of Preparation |
| 03/31/2011 | US20110076249 Immunotherapy for immune suppressed patients |
| 03/31/2011 | US20110076248 Immunizing compositions comprising hiv-1 proviral constructs with an inactive p6 gag tsg101 uev binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface. |
| 03/31/2011 | US20110076247 Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy |
| 03/31/2011 | US20110076246 Thiol-containing compounds for the removal of elements from contaminated milieu and methods of use |
| 03/31/2011 | US20110076234 Peptides comprising an isodgr motif |
| 03/31/2011 | US20110076233 Delivery System for Cytotoxic Drugs by Bispecific Antibody Pretargeting |
| 03/31/2011 | CA2775697A1 Cyclic peptide inhibitors of hepatitis c virus replication |
| 03/31/2011 | CA2774973A1 Peptidomimetic macrocycles |
| 03/31/2011 | CA2774951A1 Method of treating osteoporosis with a neurotoxin |
| 03/31/2011 | CA2774946A1 Identification of antigenic peptides from multiple myeloma cells |
| 03/31/2011 | CA2774836A1 Antagonists of dsg2 for treatment of cancer |
| 03/31/2011 | CA2774616A1 Composition and method for treatment of diabetes |
| 03/31/2011 | CA2774387A1 Novel macrocyclic inhibitors of hepatitis c virus replication |
| 03/31/2011 | CA2774296A1 Polypeptides and uses thereof |
| 03/31/2011 | CA2774288A1 Heparin cofactor ii fragments with anti-inflammatory and anti-coagulant activity |
| 03/31/2011 | CA2773978A1 Methods of treating inflammation |
| 03/31/2011 | CA2772220A1 Eye drops |
| 03/30/2011 | EP2302063A2 Intact minicells as vectors for DNA transfer and gene therapy in vitro and in vivo |
| 03/30/2011 | EP2302062A1 Identification of E2F target genes and uses thereof |
| 03/30/2011 | EP2302059A1 Modifications of hiv Env, Gag, and Pol enhance immunogenicity for genetic immunization |
| 03/30/2011 | EP2302040A1 Medical use of mRNA interferase |
| 03/30/2011 | EP2302031A1 Compositions and methods for enzymatic detachment of bacterial and fungal biofilms |
| 03/30/2011 | EP2301972A1 Method to prepare immunogenic lipopeptides comprising T-helper and B-cell epitopes |
| 03/30/2011 | EP2301971A1 Antibodies that bind both BCMA and TACI |
| 03/30/2011 | EP2301964A1 High affinity HIV T cell receptors |
| 03/30/2011 | EP2301963A1 Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| 03/30/2011 | EP2301962A2 Invention affecting GLP-1 and Exendin |
| 03/30/2011 | EP2301961A1 Sclerostin epitopes |
| 03/30/2011 | EP2301960A2 Polymer conjugates of mutated neublastin |
| 03/30/2011 | EP2301954A2 Nucleic acids and corresponding proteins entitled 282P1G3 useful in treatment and detection of cancer |
| 03/30/2011 | EP2301952A2 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| 03/30/2011 | EP2301951A1 Peptide derivative and composition for promoting tear secretion comprising the same |
| 03/30/2011 | EP2301947A2 Secreted proteins and uses thereof |
| 03/30/2011 | EP2301628A1 Methods and reagents for the treatment of immunoinflammatory disorders |
| 03/30/2011 | EP2301626A2 Antibiotic for use in local infection |
| 03/30/2011 | EP2301587A2 KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| 03/30/2011 | EP2301586A1 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |